The medicine "Sonizin" is available in encapsulatedform with modified release of the active ingredient. The active substance in the agent is tamsulosin hydrochloride. The drug is included in the group of alpha-blockers. The drug has a competitive and selective blocking effect on alpha1A-adrenergic receptors present in smooth muscles of the prostatic site of the urethra, cervix in the bladder, prostate gland.
Appointment
Means "Sonizin" instruction for use recommends the treatment of diuretic disorders caused by hyperplasia of the benign prostate.
Do not administer medication with intolerancecomponents. Caution is manifested in the presence of arterial hypotension, insufficiency of hepatic or renal function of a chronic nature (in severe course in particular).
Dosing regimen
"Sonizin" tool instructions for userecommends a capsule a day after meals. It is advisable to drink the medicine at the same time. It is forbidden to separate, crush or chew the capsules, in order to avoid disturbances in the prolonged release of the active ingredient.
Side effects
To undesirable consequences of taking a medicine"Sonizin" instructions for use include sleep disorders, retrograde ejaculation, headaches, orthostatic hypotension. The drug provokes dizziness, decreased libido, asthenia, tenderness in the chest and back, rhinitis, vomiting, palpitations, angioedema. On the basis of therapy, constipation or diarrhea, tachycardia, itching, rash, tachycardia are likely.
The preparation "Sonizin". Instructions for use. additional information
In practice, cases of poisoning by the agent are not described.Theoretically, the development of acute hypotension, tachycardia of the compensatory type is probable. To restore pressure, the patient needs to take a horizontal position. Cardiotropic therapy is recommended. In a state of overdose with the medication Sonizin (instruction for use indicates this), renal function control is necessary, general supportive treatment is indicated in accordance with the symptoms. In severe cases, vasoconstrictive drugs are introduced, bulk-replacing solutions.